gastrointestinal agents

Summary

Summary: Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Top Publications

  1. ncbi Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
  2. ncbi Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period cros
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Penn State Medical School, Department of Pediatrics, Hershey, Pennsylvania 17033 0850, USA
    Clin Ther 32:89-103. 2010
  3. ncbi Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin
    Makoto Arai
    Department of Medicine, Chiba University, Chiba, Japna
    Hepatogastroenterology 59:62-6. 2012
  4. ncbi Review article: the treatment of functional abdominal bloating and distension
    M Schmulson
    Laboratory of Liver, Pancreas and Motility, Department of Experimental Medicine Faculty of Medicine, Universidad Nacional Autonoma de Mexico UNAM, Mexico
    Aliment Pharmacol Ther 33:1071-86. 2011
  5. ncbi Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case
    Michael T Kram
    Department of Gastroenterology, Nyack Hospital, New York, USA
    Dis Colon Rectum 46:118-21. 2003
  6. ncbi Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report
    P V Hassard
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Los Angeles, California, USA
    Gastroenterology 120:995-9. 2001
  7. ncbi A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery
    N Gubergrits
    Department of Internal Diseases, Donetsk National Medical University, Donetsk, Ukraine
    Aliment Pharmacol Ther 33:1152-61. 2011
  8. ncbi Quality of life in patients with irritable bowel syndrome
    Hubert Monnikes
    Department of Medicine, Martin Luther Hospital, Academic Teaching Hospital of Charité Universitätsmedizin Berlin, Germany
    J Clin Gastroenterol 45:S98-101. 2011
  9. ncbi Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells
    V D Corleto
    Department of Digestive and Liver Diseases, 1st and 2nd Schools of Medicine, University La Sapienza, Rome, Italy
    Neurogastroenterol Motil 18:217-25. 2006
  10. ncbi Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
    Bruce C Trapnell
    Division of Pulmonary Biology, Cincinnati Children s Hospital Medical Center, and Division of Pulmonary, Sleep, and Critical Care Medicine, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH, 45229 3039, USA
    J Cyst Fibros 8:370-7. 2009

Detail Information

Publications268 found, 100 shown here

  1. ncbi Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...
  2. ncbi Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period cros
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Penn State Medical School, Department of Pediatrics, Hershey, Pennsylvania 17033 0850, USA
    Clin Ther 32:89-103. 2010
    ..The US Food and Drug Administration regulations now require all PERT products to undergo clinical efficacy and safety studies before they can be considered for marketing approval...
  3. ncbi Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin
    Makoto Arai
    Department of Medicine, Chiba University, Chiba, Japna
    Hepatogastroenterology 59:62-6. 2012
    ..The aim of this study was to investigate the effect of rikkunshito on upper gastrointestinal symptoms and the levels of acylated ghrelin (AG) in patients with FD...
  4. ncbi Review article: the treatment of functional abdominal bloating and distension
    M Schmulson
    Laboratory of Liver, Pancreas and Motility, Department of Experimental Medicine Faculty of Medicine, Universidad Nacional Autonoma de Mexico UNAM, Mexico
    Aliment Pharmacol Ther 33:1071-86. 2011
    ..Abdominal bloating and distension are common symptoms in patients with functional gastrointestinal disorders (FGIDs), however, relatively little is known about their treatment...
  5. ncbi Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case
    Michael T Kram
    Department of Gastroenterology, Nyack Hospital, New York, USA
    Dis Colon Rectum 46:118-21. 2003
    ..To our knowledge this is the second reported case of Behçet's ileocolitis successfully treated with anti-tumor necrosis factor therapy...
  6. ncbi Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report
    P V Hassard
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Los Angeles, California, USA
    Gastroenterology 120:995-9. 2001
    ..This report suggests that infliximab may be an effective new therapy for gastrointestinal BD, and perhaps other manifestations of BD as well...
  7. ncbi A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery
    N Gubergrits
    Department of Internal Diseases, Donetsk National Medical University, Donetsk, Ukraine
    Aliment Pharmacol Ther 33:1152-61. 2011
    ..Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS)...
  8. ncbi Quality of life in patients with irritable bowel syndrome
    Hubert Monnikes
    Department of Medicine, Martin Luther Hospital, Academic Teaching Hospital of Charité Universitätsmedizin Berlin, Germany
    J Clin Gastroenterol 45:S98-101. 2011
    ..Evidence also indicates that HRQoL in patients with IBS is affected by sex and psychological conditions. Careful consideration of these factors may help to individualize a therapeutic strategy to optimize long-term outcomes...
  9. ncbi Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells
    V D Corleto
    Department of Digestive and Liver Diseases, 1st and 2nd Schools of Medicine, University La Sapienza, Rome, Italy
    Neurogastroenterol Motil 18:217-25. 2006
    ..The contractile effects of SS are mediated through sstr subtype 2 and sstr subtype 1 on circular and longitudinal human colonic SMC, respectively...
  10. ncbi Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
    Bruce C Trapnell
    Division of Pulmonary Biology, Cincinnati Children s Hospital Medical Center, and Division of Pulmonary, Sleep, and Critical Care Medicine, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH, 45229 3039, USA
    J Cyst Fibros 8:370-7. 2009
    ..Pancreatic enzyme replacement therapy is critical for adequate nutrition in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)...
  11. ncbi Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy
    Srinivasa Prasad
    Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Hepatology 45:549-59. 2007
    ..42]); MANOVA for time and treatment, P=0.002. Improvement in HRQOL was related to the improvement in psychometry. CONCLUSION: Treatment with lactulose improves both cognitive function and HRQOL in patients with cirrhosis who have MHE...
  12. ncbi The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients
    Yuyuan Li
    Department of Gastroenterology and Hepatology, First Municipal People s Hospital of Guangzhou, Guangzhou Medical College, 1 Panfu Road, Guangzhou, 510180, P R China
    Dig Dis Sci 52:2942-9. 2007
    ....
  13. pmc Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia
    J Tack
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
    Gut 52:1271-7. 2003
    ..Impaired gastric accommodation is a major pathophysiological mechanism in functional dyspepsia. The aim of the present work was to assess a satiety drinking test in the evaluation of accommodation in health and dyspepsia...
  14. ncbi A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
    M Camilleri
    Glaxo Wellcome Inc, 5 Moore Dr, Research Triangle Park, NC 27709, USA
    Arch Intern Med 161:1733-40. 2001
    ..CONCLUSION: Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS...
  15. ncbi Pathophysiology and treatment of functional dyspepsia
    Jan Tack
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
    J Clin Gastroenterol 39:S211-6. 2005
    ..Thus, efforts to further elucidate underlying pathophysiologic mechanisms and identify the appropriate patient population using some type of pathophysiologic testing will be required...
  16. ncbi The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound
    M R Briejer
    Department of Gastrointestinal Pharmacology, Janssen Research Foundation, Turnhoutseweg 30, 2340 Beerse, Belgium
    Eur J Pharmacol 423:71-83. 2001
    ....
  17. pmc Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials
    Bodil Als-Nielsen
    Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Department 7102, H S Rigshospitalet, DK 2100 Copenhagen, Denmark
    BMJ 328:1046. 2004
    ..To assess the effects of non-absorbable disaccharides (lactulose and lactitol) in patients with hepatic encephalopathy...
  18. ncbi Prokinetics in acute upper GI bleeding: a meta-analysis
    Alan N Barkun
    Division of Gastroenterology, McGill University Health Center, McGill University, Montreal, Quebec, Canada
    Gastrointest Endosc 72:1138-45. 2010
    ..Recent data suggest that administration of prokinetics before gastroscopy may be useful in patients with acute upper GI bleeding (UGIB). Published studies are limited in the number of subjects evaluated, and the conclusions are disparate...
  19. pmc Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders
    Miguel Saps
    Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614, USA
    Gastroenterology 137:1261-9. 2009
    ..The aim of this study was to evaluate the efficacy of amitriptyline in children with pain-predominant functional gastrointestinal disorders...
  20. ncbi Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 36:649-64, xi-x. 2007
    ..To achieve greater therapeutic efficacy, it may be necessary to target the therapeutic approach to a specific pathophysiology, such as impaired gastric emptying...
  21. ncbi Acute pancreatitis, bacterial translocation, and different octreotide regimens: an experimental study
    Osman Güler
    Department of General Surgery, Ankara Training and Research Hospital, Ankara 06340, Turkey
    Surg Today 39:876-83. 2009
    ..To determine the effect of octreotide, octreotide with zinc, levamisole, and misoprostol on the bacterial translocation that develops in rats with acute pancreatitis (AP)...
  22. ncbi Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials
    P Schoenfeld
    Division of Gastroenterology, University of Michigan School of Medicine and Veterans Affairs Center for Excellence in Health Services Research, Ann Arbor, MI 48105, USA
    Aliment Pharmacol Ther 19:263-9. 2004
    ....
  23. ncbi A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS
    Richard Krause
    ClinSearch, Chattanooga, Tennessee, USA
    Am J Gastroenterol 102:1709-19. 2007
    ..Multiple dosing regimens were assessed in a randomized, double-blind, placebo-controlled study (S3B30040) to determine efficacy, tolerability, and evaluate constipation rate...
  24. ncbi Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial
    David C Whitcomb
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Am J Gastroenterol 105:2276-86. 2010
    ..Our objective was to assess the efficacy and safety of a new formulation of pancrelipase (pancreatin) delayed-release 12,000-lipase unit capsules (CREON) in patients with EPI due to CP or PS...
  25. ncbi Alosetron: ischemic colitis and serious complications of constipation
    Hugo Gallo-Torres
    Am J Gastroenterol 101:1080-3. 2006
    ....
  26. ncbi The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers
    Yu Kyung Cho
    Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
    J Clin Gastroenterol 40:286-92. 2006
    ..To evaluate the effect of mosapride, a selective 5-hydroxytryptamine-4 agonist, on esophageal motility and bolus transit in asymptomatic volunteers...
  27. pmc A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation
    William D Chey
    Department of Medicine, University of Michigan Health System, Ann Arbor, 48109 5362, USA
    Am J Gastroenterol 106:1803-12. 2011
    ..We conducted an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase IIb study, which evaluated A3309 in patients with chronic idiopathic constipation (CIC)...
  28. ncbi Review article: cardiac adverse effects of gastrointestinal prokinetics
    M Tonini
    Department of Internal Medicine and Therapeutics, Section of Experimental and Clinical Pharmacology, University of Pavia, Pavia, Italy
    Aliment Pharmacol Ther 13:1585-91. 1999
    ..g. ketoconazole, itraconazole, miconazole and fluconazole) and macrolide antibacterials (e.g. erythromycin, clarithrod-mycin and troleandomycin), which can inhibit cisapride metabolism by interfering with the CYP3A4 isoenzyme...
  29. pmc Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study
    Yong Han Paik
    Department of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine, Yongdong Severance Hospital, 146 92 Dogok dong, Gangnam Gu, Seoul 135 720, Korea
    Yonsei Med J 46:399-407. 2005
    ..There was no episode of renal function impairment in either treatment group. Rifaximin proved to be as safe and as effective as lactulose for the treatment of Korean patients with hepatic encephalopathy...
  30. ncbi Celiac disease: from pathogenesis to novel therapies
    Detlef Schuppan
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 137:1912-33. 2009
    ..These and other experimental therapies will be discussed critically...
  31. ncbi The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis
    Michael Safdi
    Greater Cincinnati Gastroenterology Associates, Cincinnati, OH 45219, USA
    Pancreas 33:156-62. 2006
    ..Secondary objectives included evaluation of stool parameters and global improvement of symptoms scales...
  32. ncbi Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study
    M Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:1256-e117. 2009
    ..Prucalopride up to 2 mg once daily for 4 weeks was safe and well-tolerated by constipated elderly patients, with no differences vs placebo in ECG or a range of Holter-monitoring parameters...
  33. ncbi Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography
    Junko Endo
    Department of Gastroenterology, Kochi National Hospital, Kochi, Japan
    J Gastroenterol 37:888-95. 2002
    ..However, few studies have evaluated the influence of mosapride citrate on autonomic nervous activity and hemodynamics...
  34. ncbi The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
    C W Lees
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 29:286-97. 2009
    ..Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC)...
  35. ncbi Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data
    Lin Chang
    Center for Neurovisceral Sciences and Women s Health, Department of Medicine, UCLA and VA Greater Los Angeles Healthcare Center, California, USA
    Am J Gastroenterol 101:1069-79. 2006
    ..This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance...
  36. ncbi Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study
    Tiing Leong Ang
    Department of Gastroenterology, Changi General Hospital, 2 Simei Street 3, Singapore, 529889, Singapore
    J Gastroenterol 41:647-53. 2006
    ..This randomized, double-blind study compared the efficacy of Helicobacter pylori eradication against prokinetics in H. pylori-infected functional dyspepsia patients...
  37. ncbi Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study
    Jeffrey L Anderson
    Cardiovascular Department, Intermountain Medical Center, Murray, Utah 84107, USA
    J Cardiovasc Pharmacol Ther 14:170-5. 2009
    ..This large epidemiologic study failed to confirm a reported large event differential for tegaserod that was noted incidentally in a clinical trials database, suggesting that the prior observation may have been due to chance...
  38. ncbi Effects of Baicalin and Octreotide on the serum TNF-alpha level and apoptosis in multiple organs of rats with severe acute pancreatitis
    Hua Tian
    Department of General Surgery, Affiliated Xiaoshan First People s Hospital, Hangzhou Normal University, Hangzhou, Zhejiang Province, China
    Inflammation 32:191-201. 2009
    ..05 or P < 0.01). Baicalin and Octreotide share a similar therapeutic efficacy in the treatment of SAP via a mechanism that is associated with inhibiting the levels of TNF-alpha in blood and induce apoptosis in multiple organs...
  39. ncbi Octreotide therapy for control of acute gastrointestinal bleeding in children
    Y Eroglu
    Department of Gastroenterology, Hepatology and Nutrition, Children s Memorial Hospital, Northwestern University Medical School, Chicago, IL 60614, USA
    J Pediatr Gastroenterol Nutr 38:41-7. 2004
    ..To evaluate the outcomes of octreotide use in children with gastrointestinal bleeding with or without portal hypertension...
  40. pmc Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation
    M L Manini
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 22:42-9, e7-8. 2010
    ..Velusetrag significantly accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing. Further studies of its potential as a gastrointestinal and colonic prokinetic are warranted...
  41. ncbi Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
    ..It is not known whether infliximab is an effective maintenance therapy for patients with fistulas...
  42. ncbi Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality
    J D Chen
    Division of Gastroenterology, University of Texas Medical Branch, Galveston, TX 77555 0764, USA
    Aliment Pharmacol Ther 14:1041-7. 2000
    ..We evaluated the effects of cisapride (10 mg t.d.s. and 20 mg b.d.) on gastrointestinal symptoms and gastric myoelectrical activity in patients with functional dyspepsia. Myoelectrical activity was measured by electrogastrography...
  43. pmc Pediatric patients with dyspepsia have chronic symptoms, anxiety, and lower quality of life as adolescents and adults
    Sara W Rippel
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    Gastroenterology 142:754-61. 2012
    ..Little is known about long-term health outcomes of children with dyspeptic symptoms. We studied the natural history of pediatric patients with dyspeptic symptoms, with and without histologic reflux, compared with healthy controls...
  44. ncbi Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding
    Y Bai
    Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China
    Aliment Pharmacol Ther 34:166-71. 2011
    ..Studies evaluating the effect of erythromycin on patients with acute upper gastrointestinal bleeding (UGIB) had been reported, but the results were inconclusive...
  45. ncbi Erythromycin prior to endoscopy in acute upper gastrointestinal bleeding: a meta-analysis
    Nicholas M Szary
    Division of Gastroenterology, University of Missouri School of Medicine, Columbia, MO, USA
    Scand J Gastroenterol 46:920-4. 2011
    ..Therefore, a meta-analysis was performed comparing the efficacy of erythromycin infusion prior to endoscopy in acute UGIB...
  46. pmc Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study
    V Thorat
    Department of Medical Gastroenterology, Poona Hospital and Research Centre, Pune, India
    Aliment Pharmacol Ther 36:426-36. 2012
    ..Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss...
  47. ncbi Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients
    Robert MacLaren
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    JPEN J Parenter Enteral Nutr 32:412-9. 2008
    ..The purpose of this study is to evaluate erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric enteral nutrition (EN)...
  48. ncbi Hepatic Encephalopathy
    A T Blei
    Department of Medicine, Lakeside VA Medical Center and Northwestern University, Chicago, Illinois 60611, USA
    Am J Gastroenterol 96:1968-76. 2001
    ..In patients with significant deficits or complaints, a therapeutic program based on dietary manipulations and/or nonabsorbable disaccharides may be tried. Benzodiazepines should not be used for patients with sleep difficulties...
  49. ncbi Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome
    Ron Schey
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4576 JCP, Iowa City, IA 52242, USA
    Dig Dis Sci 56:1619-25. 2011
    ..Thus far, lubiprostone offers a novel approach to our therapeutic armamentarium, however, there is a need for more drugs with different mechanisms of action, in order to treat constipation that is often multifunctional...
  50. ncbi General practitioner prescribing patterns in Babol city, Islamic Republic of Iran
    A A Moghadamnia
    Department of Pharmacology, Babol, Islamic Republic of Iran
    East Mediterr Health J 8:550-5. 2002
    ..Injections were prescribed in 58.0% of encounters. Female and male doctors had significantly different antibiotic prescribing patterns. Our study confirms the tendency of GPs to overprescribe...
  51. ncbi Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill
    Marc A Ritz
    Department of Gastrointestinal Medicine, Royal Adelaide Hospital, 5000, Adelaide, SA, Australia
    Intensive Care Med 31:949-54. 2005
    ..To compare the effectiveness of 70-mg and 200-mg doses of intravenous erythromycin in improving gastric emptying in critically ill patients...
  52. ncbi Protective effects of baicalin and octreotide on intestinal mucosa of rats with severe acute pancreatitis
    Xiping Zhang
    Department of General Surgery, Hangzhou First People s Hospital, Zhejiang Province, China
    Turk J Gastroenterol 20:108-15. 2009
    ..To compare the protective effects of baicalin and octreotide on intestinal mucosa of rats with severe acute pancreatitis and to explore the application value of baicalin as a new drug...
  53. ncbi Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial
    Dominique Pateron
    Emergency Department, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, Pierre et Marie Curie Paris 6 University, Paris, France
    Ann Emerg Med 57:582-9. 2011
    ..We determine whether in acute upper gastrointestinal bleeding the frequency of satisfactory stomach visualization was different after intravenous erythromycin, a nasogastric tube with gastric lavage, or both...
  54. ncbi Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis
    Fumio Omata
    St Luke s International Hospital, 9 1 Akashichyo, Chuoku, Tokyo 104 8560, Japan
    J Gastroenterol 45:885-95. 2010
    ..Previous meta-analyses and randomized controlled trials have shown conflicting results regarding the preventive efficacy of somatostatin or octreotide for this complication. The aim of this study was to resolve these conflicts...
  55. ncbi Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
    Alexander P Bryant
    Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA 02141, USA
    Life Sci 86:760-5. 2010
    ....
  56. ncbi 5-HT4 receptor agonists: similar but not the same
    J H De Maeyer
    Movetis NV, Turnhout, Belgium
    Neurogastroenterol Motil 20:99-112. 2008
    ..Selective 5-HT(4) receptor agonists might thus prove to be innovative drugs with an attractive safety profile for better treatment of patients suffering from hypomotility disorders...
  57. ncbi Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial
    Nicholas Carbonell
    Service d Hepatologie, Hopital Saint Antoine, Paris, France
    Am J Gastroenterol 101:1211-5. 2006
    ..We investigated whether the association of erythromycin infusion to gastric lavage could improve stomach cleansing before endoscopy...
  58. pmc Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach
    Pascal G Leclere
    Heymans Institute of Pharmacology, Ghent University, Faculty of Medicine and Health Sciences, De Pintelaan 185, B 9000 Ghent, Belgium
    Br J Pharmacol 135:135-42. 2002
    ..No evidence for modulation by NO or VIP was obtained...
  59. ncbi The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat
    J L McCullough
    Department of Pharmacology, Theravance Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Pharmacol Res 53:353-8. 2006
    ..The clinical relevance of the 5-HT2B receptor antagonism of tegaserod remains to be determined...
  60. ncbi Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission
    Andrew Szilagyi
    Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Dig Dis Sci 47:2811-22. 2002
    ..In conclusion, although controls adapt to a 3-week period of lactulose ingestion, IBD patients fail to meet the criteria for adaptation. However, longer studies may be needed to establish whether IBD patients are slower to adapt...
  61. ncbi Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization
    Ki Suk Kim
    Department of Pharmacology and National Research Laboratory, Korea Institute of Toxicology, Korea Research Institute of Chemical Technology, Yuseong, Daejeon, Korea
    Int J Toxicol 26:25-31. 2007
    ..But, in a supratherapeutic concentration that might possibly be encountered during overdose or impaired metabolism, clebopride may have torsadogenic potency...
  62. ncbi Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation
    Kwong M Fock
    Changi General Hospital, Singapore, Singapore
    J Gastroenterol Hepatol 22:1190-8. 2007
    ....
  63. ncbi Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation
    Stefan Müller-Lissner
    Park Klinik Weissensee, Berlin, Germany
    Am J Gastroenterol 101:2558-69; quiz 2671. 2006
    ..To assess the long-term safety and tolerability of tegaserod in patients with chronic constipation (CC)...
  64. ncbi Prucalopride: a new drug for the treatment of chronic constipation
    Jan Tack
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Gastroenterol Hepatol 3:337-43. 2009
    ..The Phase III studies mainly recruited patients with insufficient response to laxatives, and showed consistent efficacy and excellent tolerability for prucalopride...
  65. ncbi The effect of octreotide as an adjunct treatment in active nonvariceal upper gastrointestinal bleeding
    Vassiliki N Nikolopoulou
    Department of Internal Medicine, Division of Gastroenterology, University Hospital, Patras, Greece
    J Clin Gastroenterol 38:243-7. 2004
    ..The aim of this study was to determine the effect ofoctreotide on active or recent gastrointestinal bleeding from benign peptic ulcers...
  66. ncbi The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease
    Caterina Finizia
    Departments of Otorhinolaryngology and Surgery, Sahlgrenska University Hospital, 413 45 Goteborg, Sweden
    Eur J Gastroenterol Hepatol 14:9-14. 2002
    ..To evaluate the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastro-oesophageal reflux...
  67. ncbi Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study
    Mats Sjöberg
    Department of Medicine, Skaraborgs Hospital, Lidköping, Sweden
    Inflamm Bowel Dis 18:212-8. 2012
    ..Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC). There are no data comparing the efficacy of these two alternatives...
  68. ncbi Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia
    R Ohki
    Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi 329 0498, Japan
    Pacing Clin Electrophysiol 24:119-21. 2001
    ..48 to 0.56 seconds and self-terminating torsades de pointes occurred. We considered that this proarrhythmia was induced by mosapride in combination with antiarrhythmic agents...
  69. ncbi Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study
    J Levy
    Babies and Children s Hospital of New York, Columbia University College of Physicians and Surgeons, New York 10032 3784, USA
    J Pediatr Gastroenterol Nutr 32:458-63. 2001
    ..This study sought to analyze electrocardiograms (ECGs) from a multicenter pediatric study and to identify abnormalities in QTc interval associated with cisapride use...
  70. ncbi Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis
    Praveen Sharma
    Department of Gastroenterology, G B Pant Hospital, New Delhi, India
    Hepatobiliary Pancreat Dis Int 9:27-32. 2010
    ..Diagnosis of MHE requires cumbersome tests. Lactulose is effective in the treatment of MHE. This study aimed to evaluate the use of critical flicker frequency (CFF) for the diagnosis of MHE in cirrhotic patients after treatment...
  71. ncbi Coprescribing and codispensing of cisapride and contraindicated drugs
    J K Jones
    Director of Research, The Degge Group, Ltd, 1616 N Fort Myer Dr, No. 1430, Arlington, VA 22209, USA
    JAMA 286:1607-9. 2001
    ..The pharmacy may be an important and underutilized intervention point to prevent contraindicated drugs from being used together...
  72. ncbi Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure
    C M Nzerue
    Department of Medicine, Renal Section, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Int J Artif Organs 26:86-9. 2003
    ..Our experience suggests that use of octerotide to treat refractory or prolonged sulfonylurea-included hypoglycemia in renal failure patients is safe and effective; large prospective studies would be needed to validate these findings...
  73. ncbi Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population
    I Migeon-Duballet
    CHU de Poitiers, Hopital La Miletrie, Poitiers, France
    Curr Med Res Opin 22:1227-35. 2006
    ..The study also attempted an economic evaluation of the use of PEG+E in this setting...
  74. pmc Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function
    Suwebatu T Odunsi-Shiyanbade
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 8:159-65. 2010
    ..Di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), and bile acid binding have unclear effects on colonic transit in health and disease...
  75. ncbi The proximal colonic motor response to rectal mechanical and chemical stimulation
    P A Bampton
    Department of Gastroenterology, The St George Hospital, University of New South Wales, Sydney, Australia 2217
    Am J Physiol Gastrointest Liver Physiol 282:G443-9. 2002
    ..Rectal distension inhibits all colonic motor activity...
  76. ncbi Pilot study on the effect of linaclotide in patients with chronic constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA, USA
    Am J Gastroenterol 104:125-32. 2009
    ..In Phase 1 studies in healthy human volunteers, linaclotide was well-tolerated, increased bowel movement frequency, and loosened stool consistency...
  77. ncbi Effect of tegaserod on gut transit in male and female subjects
    L Degen
    Department of Research and Clinical Research Center, University Hospital, Basel, Switzerland
    Neurogastroenterol Motil 17:821-6. 2005
    ..The results imply that tegaserod is a potent prokinetic agent throughout the GI in both sexes...
  78. ncbi Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel
    F Potet
    , , Nantes, France
    J Pharmacol Exp Ther 299:1007-12. 2001
    ..We also conclude that 5-HT4 agonists devoid of side effects on the HERG current such as mosapride can be found as a safe alternative to cisapride...
  79. ncbi Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial
    John F Johanson
    University of Illinois College of Medicine, Rockford, IL, USA
    Clin Gastroenterol Hepatol 2:796-805. 2004
    ..Chronic constipation is a common gastrointestinal disorder. The aim of this study was to evaluate the efficacy, safety, and tolerability of tegaserod, a serotonin subtype 4 receptor partial agonist in patients with chronic constipation...
  80. ncbi Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans
    Ursula Schwab
    Department of Clinical Nutrition, University of Kuopio, Finland
    J Nutr 136:34-8. 2006
    ..In conclusion, a single dose of orally administered betaine had an acute and dose-dependent effect on serum betaine concentration and resulted in lowered plasma tHcy concentrations within 2 h in healthy subjects...
  81. ncbi Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease
    Meena Thayu
    Division of Gastroenterology and Nutrition, The Children s Hospital of Philadelphia, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    J Pediatr Gastroenterol Nutr 40:220-2. 2005
  82. ncbi Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis
    Xi Ping Zhang
    Department of General Surgery, Hangzhou First People s Hospital, 261 Huansha Road, Hangzhou, Zhejiang Province 310006, China
    Dig Dis Sci 53:581-91. 2008
    ..To discuss the application value of Baicalin which is a new drug by comparing the protecting effects of Baicalin and Octreotide on multiple organs (pancreas, liver, kidney, and lung) in Severe acute pancreatitis (SAP)...
  83. ncbi Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy
    Wei Wei
    Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    J Gastroenterol Hepatol 22:1605-8. 2007
    ..The aim of this study was to determine the effect of oral mosapride on gastrointestinal transit time and the diagnostic yield of CE...
  84. ncbi Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children
    Christophe Dupont
    Hopital Saint Vincent de Paul, Service de Neonatologie, Paris, France
    J Pediatr Gastroenterol Nutr 41:625-33. 2005
    ..To assess the safety of a polyethylene glycol (PEG) 4000 laxative without additional salts in pediatric patients...
  85. pmc Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gut 54:1224-31. 2005
    ..The safety and effect of teduglutide were investigated in SBS patients with and without a colon in continuity...
  86. ncbi A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation
    Jack A Di Palma
    Division of Gastroenterology, University of South Alabama College of Medicine, Mobile, Alabama 36693, USA
    Am J Gastroenterol 102:1964-71. 2007
    ..This study was designed to compare the efficacy of each product over a 4-wk treatment period...
  87. ncbi Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials
    Anthony J Lembo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 2:675-82. 2004
    ..The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)...
  88. ncbi Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial
    G Stacher
    Department of Surgery, University of Vienna, Austria
    J Clin Endocrinol Metab 84:2357-62. 1999
    ..Blood glucose levels before and during assessment of emptying did not affect emptying, but the glucose rise over fasting levels was greater with faster emptying...
  89. ncbi Pharmacological effects of oxytocin on gastric emptying and intestinal transit of a non-nutritive liquid meal in female rats
    Chiu Lung Wu
    Department of Physiology, School of Medicine, National Yang Ming University, Shih Pai, Taipei 11221, Taiwan, Republic of China
    Naunyn Schmiedebergs Arch Pharmacol 367:406-13. 2003
    ..These results suggest that OT inhibits gastric emptying and gastrointestinal transit in female rats via a mechanism involving CCK stimulation and CCK(1) receptor activation...
  90. ncbi Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study
    Carla Colombo
    CF Center of Milano, Fondazione IRCCS Ospedale Policlinico, Mangiagalli, Regina Elena, Milano, and University of Milan, Milan, Italy
    Pancreas 38:693-9. 2009
    ..To evaluate the efficacy and safety of a pancreatic enzyme preparation specifically developed for infants and small children with cystic fibrosis (CF)...
  91. ncbi Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome
    Kevin Olden
    Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Am J Gastroenterol 97:3139-46. 2002
    ....
  92. pmc Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia
    C Feinle
    Gastroenterology Division, University Hospital Zurich, Switzerland
    Gut 48:347-55. 2001
    ....
  93. ncbi Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome
    G Tougas
    Medicine and Gastroenterology, McMaster University Medical Center, Hamilton, Canada
    Aliment Pharmacol Ther 16:1701-8. 2002
    ..Tegaserod is a 5-hydroxytryptamine-4 receptor partial agonist. Oral administration causes gastrointestinal effects resulting in increased gastrointestinal motility and attenuation of visceral sensation...
  94. pmc Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis
    Archana S Rao
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Biomedical Statistics and Informatics, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 139:1549-58, 1558.e1. 2010
    ..Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C)...
  95. pmc Lubiprostone: a novel treatment for chronic constipation
    Brian E Lacy
    Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Clin Interv Aging 3:357-64. 2008
    ..This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication...
  96. pmc Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum
    C Bhatia
    Royal Brompton and Harefield NHS Trust, Paediatric Surgical Unit, Harefield Hospital, Harefield, Middlesex UB9 6JH, UK
    Arch Dis Child 85:234-5. 2001
    ..We believe this to be the first report of successful use of octreotide in iatrogenic chyloperitoneum in a child...
  97. ncbi Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies
    D A Drossman
    University of North Carolina Center for Functional Gl and Mobility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Aliment Pharmacol Ther 29:329-41. 2009
    ..Effective treatments for irritable bowel syndrome with constipation (IBS-C) are lacking...
  98. ncbi Infliximab for patients with refractory ulcerative colitis
    W Y Chey
    Rochester Institute for Digestive Disease and Sciences, New York 14607, USA
    Inflamm Bowel Dis 7:S30-3. 2001
    ..001). In conclusion, infliximab improved clinical, endoscopic, and histologic outcomes in patients with severely active UC refractory to conventional therapy, allowing corticosteroid sparing and reducing the need for colectomy...
  99. pmc Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial
    N J Talley
    Department of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia
    Gut 49:395-401. 2001
    ..CONCLUSIONS: The motilin agonist ABT-229 was not efficacious in the relief of postprandial symptoms in diabetes mellitus in the presence or absence of delayed gastric emptying...
  100. ncbi Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study
    R Williams
    Liver Research Unit, King s College Hospital, London, UK
    Eur J Gastroenterol Hepatol 12:203-8. 2000
    ..To determine the efficacy, tolerability and safety of oral rifaximin given at three dose levels in patients with cirrhosis and mild to moderate hepatic encephalopathy (HE)...
  101. ncbi Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety
    J F Johanson
    Rockford Gastroenterology Associates, Rockford, IL, USA
    Aliment Pharmacol Ther 25:1351-61. 2007
    ..Lubiprostone, a locally acting type-2 chloride channel activator, induces intestinal fluid secretion...

Research Grants66

  1. ESTABLISHMENT AND EXPANSION OF A SPF RHESUS COLONY: AIDS, GENOME
    Rudolf P Bohm; Fiscal Year: 2011
    ..of morbidity and mortality in the TNPRC SPF breeding colonies, we plan to screen animals for selected gastrointestinal agents to further clarify their roles in disease and develop prevention and possible treatment strategies...
  2. AMIA 2002 Spring Congress: A Drug By Any Other Name
    Daniel Sands; Fiscal Year: 2002
    ..abstract_text> ..
  3. NOVEL MAGAININ DRUGS FOR PSEUDOMEMBRANOUS COLITIS
    W Maloy; Fiscal Year: 1992
    ..This project may yield important gastrointestinal drugs with improved potency against C. difficile and excellent market potential. It will also advance the fields of peptide antibiotics and host defense therapy...
  4. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  5. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  6. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  7. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  8. IMURAN Dose Ranging Study in Crohn's Disease
    BRUCE SANDS; Fiscal Year: 2005
    ..Abstract Not Provided ..
  9. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
  10. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  11. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  12. Colonic Bacterial Synthesis of Butyric Acid
    CRAIG KIEN; Fiscal Year: 2004
    ....
  13. DIFFERENTIAL METABOLISM OF DIETARY FATTY ACIDS
    CRAIG KIEN; Fiscal Year: 2003
    ..In specific aim 4, the PI will measure the thermic effect of feeding during both the solid food and formula diet periods. The PI hypothesizes that the high OA feeding will be associated with a higher thermic effect of feeding. ..
  14. Mechanisms for differential effects of dietary fatty acids on metabolism
    CRAIG LAWRENCE KIEN; Fiscal Year: 2010
    ..important new information regarding how mitochondrial malfunction, modified by dietary FA, plays a central role in the development of obesity, the metabolic syndrome, type 2 diabetes, and both heritable and age-related metabolic diseases ..
  15. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  16. Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2005
    ..This conference will provide a forum where thought leaders focused on the molecular and cellular basis or clinical management of PAP will present cutting edge research, integrate concepts, and chart innovative research directions. ..
  17. Regulation of Alveolar Macrophage Phagocytosis
    Bruce Trapnell; Fiscal Year: 2006
    ..1, and Hck/SFKs in AMs. Results of this research are expected to help establish the feasibility of the therapeutic use of GM-CSF in the treatment of lung infections by a wide variety of microbial pathogens. ..
  18. NF-kB in the intestinal radiation response
    Laurence Egan; Fiscal Year: 2005
    ..These results will provide mechanistic insight into an important medically relevant problem, amd will point the way towards novel therapies to prevent radiation injury to the intestines. ..
  19. Fourth Annual International Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  20. IKK Beta In Intestinal Inflammation
    Laurence Egan; Fiscal Year: 2005
    ..abstract_text> ..
  21. Conference--Pulmonary Alveolar Proteinosis Research
    Bruce Trapnell; Fiscal Year: 2004
    ..Recent progress in PAP research represents a paradigm of the intersection of basic science, clinical medicine and translational research, which has taken this disease from obscurity to clarity in a decade. ..
  22. AAT Deficiency & Liver Diseases Caused by Proteins
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  23. GM-CSF & Alveolar Macrophage Antiviral Lung Defense
    Bruce Trapnell; Fiscal Year: 2004
    ..abstract_text> ..
  24. BIOLOGY OF HUMAN INTRAEPITHELIAL LYMPHOCYTES
    Ellen Ebert; Fiscal Year: 2002
    ..These studies will determine the mechanism of IEL chemotaxis toward secreted products of ECs, why IL-15 is more potent than IL-2 in inducing LAK activity by IELs, and how IL-10 and IL-12 augment this activity. ..
  25. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  26. GROWTH AND DEATH SIGNALS IN THE PROSTATE
    Maria Abreu; Fiscal Year: 2002
    ..After this three year period of training, I will return to gastrointestinal research with the support of my co-sponsor and begin to develop intestinal models to study normal and pathologic states of apoptosis. ..
  27. Impact of Medicaid Prescription Copayments in Patients with Schizophrenia
    Jalpa Doshi; Fiscal Year: 2009
    ..The findings of our study will help inform policymakers about the intended and unintended consequences of prescription copayments in Medicaid patients with schizophrenia. ..
  28. Music Therapy for Cancer Patients at the End of Life
    Kristine Nelson; Fiscal Year: 2004
    ....
  29. Dietary Treatment of Crohn's Disease
    Ece Mutlu; Fiscal Year: 2007
    ..Significance. This study could provide information to suggest diet as a safe therapy for IBD and lay the groundwork for more definitive, randomized, controlled trials. ..
  30. INDUCTION OF APOPTOSIS BY HIV-1 INFECTED MONOCYTIC CELLS
    Lloyd Mayer; Fiscal Year: 2007
    ..abstract_text> ..
  31. MEDIATORS AND MODULATION OF NOCICEPTION
    Gerald Gebhart; Fiscal Year: 2008
    ..Better appreciation of these differences will enhance our understanding of the contributions these cells make to nociceptive processing, including their role in mechanisms of hyperalgesia. ..
  32. Prenatal Exposure to Polyfluoroalkyl Compounds in the EMA Study
    Lisa A Croen; Fiscal Year: 2010
    ..In the long-term, a better understanding of the underlying biology may suggest appropriate strategies for early intervention and contribute to the eventual prevention of this often devastating and usually life-long disability. ..
  33. NATURAL AND INDUCED IMMUNITY AGAINST HELICOBACTER PYLORI
    Pierre Michetti; Fiscal Year: 2001
    ..felis infection and during mucosal immunization in both mice and humans. These studies may also contribute to the development of effective vaccination strategies against other enteric pathogens. ..
  34. VIP-induced gene expression in colonic smooth muscle cells
    Sushil K Sarna; Fiscal Year: 2010
    ..abstract_text> ..
  35. Gastric Tube Placement in Young Children
    Marsha Ellett; Fiscal Year: 2008
    ..Results from this study will increase the safety of using gastric tubes in young children. ..
  36. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  37. Prenatal and Neonatal Biologic Markers for Autism
    Lisa Croen; Fiscal Year: 2006
    ..abstract_text> ..
  38. Gastrointestinal Biopsychosocial Research Center
    William Whitehead; Fiscal Year: 2008
    ..The proposed Center is university wide and includes investigators from psychology, psychiatry, surgery (gynecology division), neuroradiology, dentistry, and the school of public health. [unreadable] [unreadable]..
  39. New Approach to Detect CP and Brain Injury by Term Age
    RONALD ARIAGNO; Fiscal Year: 2003
    ..It is essential to discover a new approach to identify brain injury early, before it will be possible to effectively investigate interventions that can improve neurological outcome of these high risk very premature infants. ..
  40. MUCOSAL T-CELLS IN EARLY&LATE PEDIATRIC CROHN'S DISEASE
    Subra Kugathasan; Fiscal Year: 2005
    ..abstract_text> ..
  41. Cognitive Modulation of Human Neuroendocrine Stress Axis
    James Abelson; Fiscal Year: 2005
    ..Existing animal data will be used to identify factors within the cognitive intervention which likely account for its potency and dismantling studies will be done to examine the separable effects of these factors. ..
  42. SEROTONIN'S ROLE IN PSYCHOBIOLOGY OF ANOREXIA NERVOSA
    Evelyn Attia; Fiscal Year: 2005
    ..The long-term goal of this award is for the candidate to become an expert and independent researcher in the psychobiology of eating disorders, with special application to anorexia nervosa. ..
  43. REDUCING SERVICE USE IN OLDER PRIMARY CARE PATIENTS
    Joshua Klapow; Fiscal Year: 2003
    ..2. Obtain training experiences that will facilitate the integration of research findings into the development and evaluation of geriatric primary care delivery systems. ..
  44. ANIMAL MODELS OF COLD AIR-INDUCED AIRWAY DISEASE
    Michael Davis; Fiscal Year: 2004
    ..The investigators will use these same measurements to determine the changes in pulmonary mechanics and airway inflammation in dogs that perform repeated exercise in frigid environments. ..
  45. 14th Internatinal Symposium on Inherited Diseases
    David Whitcomb; Fiscal Year: 2004
    ..The format, venue, and content are designed to maximize participation, education, translation and implementation of the key elements of the many new findings in the genetics of the pancreas. ..
  46. Advancing the Treatment of Fecal & Urinary Incontinence
    William Whitehead; Fiscal Year: 2003
    ..The conference is scheduled to take place November 3-5, 2002, in Milwaukee, and half of the invitees have accepted invitations to speak. ..
  47. Oral Tolerance: Mechanisms and Applications
    Lloyd Mayer; Fiscal Year: 2003
    ....
  48. The Role of Food Viscosity in Calorie Intake Regulation
    Terry Davidson; Fiscal Year: 2005
    ....
  49. SIMPLE VERTEBRATE AND INVERTEBRATE SYSTEMS
    Michael Gershon; Fiscal Year: 2005
    ..Almost all trainees have continued to be productive in biomedical science and some have acquired leadership positions. ..
  50. Pharmacogenetics of Methadone
    C Devane; Fiscal Year: 2003
    ..This study will form the basis for subsequent studies which should provide a more rational basis for dosing of methadone in pregnant addicts. ..
  51. EVALUATION OF CHD IN MEN AND WOMEN PRIOR TO FIRST AMI
    Barbara Yawn; Fiscal Year: 2002
    ..In addition, we will provide specific information on current gender-related practice patterns. This information can be used to inform future practice recommendations. ..
  52. Protection from Fas-mediated apoptosis in the gut
    Maria Abreu; Fiscal Year: 2002
    ..The support from this R03 will permit me to successfully compete for an R01 and make the transition to an independent investigator. ..
  53. Development of the enteric nervous system: Cells & genes
    Michael Gershon; Fiscal Year: 2006
    ..The invited speakers include all of the leading researchers in the field, including Professor Nicole Le Douarin. We also anticipate that many post-graduate students and post-doctoral fellows will also attend. [unreadable] [unreadable]..
  54. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  55. The CNS and cirrhosis:psychobiological approaches
    Charmaine Stewart; Fiscal Year: 2006
    ..Additionally, the proposed studies will be guided by a team of mentors and sponsors and supplemented by a didactic curriculum, all to lay the foundation for eventual independent clinical investigator status. ..
  56. MOLECULAR GENETICS OF HEREDITARY PANCREATITIS
    David Whitcomb; Fiscal Year: 2008
    ..The HP and familial pancreatitis studies are especially important because of the statistical power of family studies and the ability to detect modifier genes in a uniform background of susceptibility factors. ..
  57. Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by Proteomics
    Detlef Schuppan; Fiscal Year: 2008
    ..Adaptation to the human proteome and prospective validation shall allow noninvasive monitoring of fibrosis progression and regression in patients with liver diseases. [unreadable] [unreadable] [unreadable]..
  58. Sphingosine Kinase Inhibitors as Anti-IBD Agents
    LYNN MAINES; Fiscal Year: 2007
    ..Upon the completion of these experiments, we will be ready to begin clinical testing of the single best drug candidate. [unreadable] [unreadable] [unreadable]..
  59. NAPS2 Continuation - Genome-Wide Association Study of Pancreatitis
    David C Whitcomb; Fiscal Year: 2010
    ..Knowledge of the genetic basis of pancreatitis will lead to new treatments, and help remove the stigma that chronic pancreatitis is only a disease of drunkards. ..
  60. Mouse Models for Celiac Disease
    Detlef Schuppan; Fiscal Year: 2007
    ..g. by immunomodulatory cytokines or by cytokine antagonists. It is anticipated that the results will improve our understanding and management of cd and related autoimmune diseases. ..
  61. Regulation of spinal NK1R expression by chronic stress
    Sylvie Bradesi; Fiscal Year: 2006
    ..This proposal is expected to provide new insights into the mechanisms by which stress affects the processing of visceral nociception. ..
  62. Drug-Induced sudden death & ventricular arrhythmia
    Sean Hennessy; Fiscal Year: 2008
    ..Finally, this project will create a valuable and lasting pharmacoepidemiologic data resource that can be brought to bear in future drug safety studies. [unreadable] [unreadable]..